Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and Connected Persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
- Transaction Price: Ordinary Shares at 1369.00 pence per share; American Depositary Shares (ADSs) at $41.80 per ADS.
- Transaction Type: Notional increases in share interests following the re-investment of dividends paid on July 9, 2015.
Material Changes
The filing details specific increases in notional shareholdings for various executives and connected persons. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that notional dividends will be paid out based on the percentage of plan holdings that vest after the relevant measurement period.
Investor Verification Points
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares issued or reserved under the plan to assess potential dilution.
- Review the company's broader financial reports (e.g., Form 20-F) for actual revenue and profit metrics, as this filing contains none.